Literature DB >> 15339974

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.

Anja Verhulst1, Patrick C D'Haese, Marc E De Broe.   

Abstract

The proximal tubular cells of the kidney are responsible for reabsorption of proteins from the tubular lumen. In a study using Opossum kidney (OK) cells, receptor-mediated protein endocytosis was reduced by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which are widely used for therapeutic reduction of plasma cholesterol levels. To explore the possible clinical relevance of the observations in OK cells, protein endocytosis in human kidney tubular cells was investigated in the presence and absence of statins. The uptake of FITC-labeled albumin in these cultures of human kidney tubular cells was investigated by microscopy, flow cytometry and spectrofluorometry. Protein uptake occurred selectively into proximal tubular cells while it was absent in distal tubular/collecting duct cells. Three statins (simvastatin, pravastatin, and rosuvastatin) significantly inhibited the uptake of protein in a concentration-dependent way. This inhibitory effect of statins could be prevented by the co-addition of mevalonate, the product of HMG-CoA reductase. This effect was not the result of a statin-induced cytotoxicity since cell-viability was unaffected. Finally, it was demonstrated that statins strongly inhibited cholesterol synthesis in the human kidney tubular cells. These data suggest that statins have the potential to inhibit albumin uptake by the human proximal nephron as a result of inhibition of HMG-CoA reductase in the proximal tubule cells. Taken into account the data of the accompanying manuscript this inhibitory effect most probably results from a reduced prenylation of some proteins critically involved in endocytosis. It is suggested that these data help to explain the occurrence of proteinuria in some patients treated with high statin doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339974     DOI: 10.1097/01.ASN.0000136778.32499.05

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

Review 1.  Statins and proteinuria.

Authors:  Donald G Vidt
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 2.  Other than potency, are all statins the same?

Authors:  Nicola Abate; Manisha Chandalia
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

Review 3.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

Review 4.  The proximal tubule and albuminuria: really!

Authors:  Landon E Dickson; Mark C Wagner; Ruben M Sandoval; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 10.121

Review 5.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

6.  Multiple factors influence glomerular albumin permeability in rats.

Authors:  Ruben M Sandoval; Mark C Wagner; Monica Patel; Silvia B Campos-Bilderback; George J Rhodes; Exing Wang; Sarah E Wean; Sherry S Clendenon; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 10.121

7.  Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).

Authors:  Azan S Binbrek; Avishay Elis; Muayed Al-Zaibag; Jaan Eha; Irena Keber; Ada M Cuevas; Swati Mukherjee; Thomas R Miller
Journal:  Curr Ther Res Clin Exp       Date:  2006-01

8.  Macrophage stimulating protein may promote tubular regeneration after acute injury.

Authors:  Vincenzo Cantaluppi; Luigi Biancone; Giuseppe Mauriello Romanazzi; Federico Figliolini; Silvia Beltramo; Francesco Galimi; Maria Gavina Camboni; Elisa Deriu; Piergiulio Conaldi; Antonella Bottelli; Viviana Orlandi; Maria Beatriz Herrera; Alfonso Pacitti; Giuseppe Paolo Segoloni; Giovanni Camussi
Journal:  J Am Soc Nephrol       Date:  2008-07-09       Impact factor: 10.121

Review 9.  Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus.

Authors:  Richard Bouley; Udo Hasler; Hua A J Lu; Paula Nunes; Dennis Brown
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 10.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Authors:  Venkata M Alla; Vrinda Agrawal; Andrew DeNazareth; Syed Mohiuddin; Sudha Ravilla; Marc Rendell
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.